Vanguard Group’s Co-Diagnostics CODX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $323K | Buy |
63,637
+6,772
| +12% | +$73.7K | ﹤0.01% | 4025 |
|
|
2025
Q3 | $587K | Sell |
56,865
-910
| -2% | -$8.46K | ﹤0.01% | 3910 |
|
|
2025
Q2 | $485K | Sell |
57,775
-1,498
| -3% | -$14K | ﹤0.01% | 3926 |
|
|
2025
Q1 | $551K | Hold |
59,273
| – | – | ﹤0.01% | 3863 |
|
|
2024
Q4 | $1.33M | Sell |
59,273
-103
| -0.2% | -$3.25K | ﹤0.01% | 3673 |
|
|
2024
Q3 | $2.23M | Hold |
59,376
| – | – | ﹤0.01% | 3525 |
|
|
2024
Q2 | $2.23M | Hold |
59,376
| – | – | ﹤0.01% | 3524 |
|
|
2024
Q1 | $2M | Hold |
59,376
| – | – | ﹤0.01% | 3596 |
|
|
2023
Q4 | $2.37M | Hold |
59,376
| – | – | ﹤0.01% | 3545 |
|
|
2023
Q3 | $1.89M | Hold |
59,376
| – | – | ﹤0.01% | 3606 |
|
|
2023
Q2 | $1.98M | Hold |
59,376
| – | – | ﹤0.01% | 3662 |
|
|
2023
Q1 | $2.64M | Hold |
59,376
| – | – | ﹤0.01% | 3577 |
|
|
2022
Q4 | $4.49M | Buy |
59,376
+5,897
| +11% | +$552K | ﹤0.01% | 3354 |
|
|
2022
Q3 | $5.15M | Sell |
53,479
-13,962
| -21% | -$1.95M | ﹤0.01% | 3308 |
|
|
2022
Q2 | $11.4M | Buy |
67,441
+5,044
| +8% | +$767K | ﹤0.01% | 2923 |
|
|
2022
Q1 | $11.6M | Buy |
62,397
+2,562
| +4% | +$530K | ﹤0.01% | 3074 |
|
|
2021
Q4 | $16M | Sell |
59,835
-91
| -0.2% | -$23.9K | ﹤0.01% | 2953 |
|
|
2021
Q3 | $17.5M | Sell |
59,926
-1,695
| -3% | -$495K | ﹤0.01% | 2936 |
|
|
2021
Q2 | $15.3M | Buy |
61,621
+605
| +1% | +$156K | ﹤0.01% | 2983 |
|
|
2021
Q1 | $17.5M | Buy |
61,016
+7,220
| +13% | +$2.88M | ﹤0.01% | 2852 |
|
|
2020
Q4 | $15M | Buy |
53,796
+5,032
| +10% | +$1.86M | ﹤0.01% | 2781 |
|
|
2020
Q3 | $19.9M | Buy |
48,764
+5,355
| +12% | +$2.75M | ﹤0.01% | 2467 |
|
|
2020
Q2 | $25.2M | Buy |
43,409
+17,502
| +68% | +$7.99M | ﹤0.01% | 2305 |
|
|
2020
Q1 | $5.92M | Buy |
25,907
+6,205
| +31% | +$1.08M | ﹤0.01% | 2898 |
|
|
2019
Q4 | $529K | Hold |
19,702
| – | – | ﹤0.01% | 3785 |
|
|
2019
Q3 | $609K | Buy |
19,702
+8,363
| +74% | +$278K | ﹤0.01% | 3773 |
|
|
2019
Q2 | $281K | Buy |
11,339
+6,656
| +142% | +$186K | ﹤0.01% | 3917 |
|
|
2019
Q1 | $149K | Buy |
4,683
+3,013
| +180% | +$108K | ﹤0.01% | 3966 |
|
|
2018
Q4 | $74K | Sell |
1,670
-1,508
| -47% | -$98.5K | ﹤0.01% | 4034 |
|
|
2018
Q3 | $251K | Buy |
3,178
+501
| +19% | +$49.5K | ﹤0.01% | 3974 |
|
|
2018
Q2 | $312K | Buy |
2,677
+1,591
| +147% | +$130K | ﹤0.01% | 3910 |
|
|
2018
Q1 | $71K | Buy |
1,086
+86
| +9% | +$6.56K | ﹤0.01% | 4054 |
|
|
2017
Q4 | $82K | Buy |
+1,000
| New | +$150K | ﹤0.01% | 4009 |
|
Other funds holding CODX
PAG
KAS
Vanguard Group's CODX Position: Q4 2025 in Review
Vanguard Group increased its Co-Diagnostics (CODX) stake by 12% in Q4 2025, buying an estimated $73.7K and bringing the position to 63,637 shares worth $323K. The position accounts for ﹤0.01% of the portfolio, ranked #4025.
Vanguard Group first reported a position in CODX in Q4 2017 and has held it in 33 quarters since. The position peaked at $25.2M in Q2 2020. 30 funds tracked by Wall St. Rank hold CODX as of Q4 2025.
- Vanguard Group held 63,637 shares of Co-Diagnostics worth $323K as of Q4 2025.
- Vanguard Group bought 6,772 Co-Diagnostics shares in Q4 2025, an estimated $73.7K.
- Co-Diagnostics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #4025 holding.
- Vanguard Group first reported a position in Co-Diagnostics in Q4 2017 and has held it in 33 quarters since.
- Vanguard Group's Co-Diagnostics position peaked at $25.2M in Q2 2020.
- 30 funds tracked by Wall St. Rank held Co-Diagnostics as of Q4 2025.
Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.